Alkermes Plc. (ALKS)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

88 SIDNEY ST CAMBRIDGE, MA 02139-4136

Alkermes Plc. develops products based on sophisticated drug delivery technologies to enhance therapeutic outcomes in major diseases. Headquartered in Cambridge, MA, this pharmaceutical company also operates research and manufacturing facilities in Massachusetts and Ohio.

Data as of 2020-08-09
Market Cap2.973 Billion Shares Outstanding159.044 Million Avg 30-day Volume1.566 Million
P/E Ratio Dividend Yield EPS-0.8
Price/Sales2.559 Price cash flow ratio104.2 Price free cash flow ratio-47.7
Book Value6.68 Price to Tangible Book3.55 Alpha-0.02
Short Interest Ratio % Short Interest to Float R-squared0.188463
BETA1.4043 52-week High/Low23.22 / 11.98 Stddev0.136026
View SEC Filings from ALKS instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 4 3 (0.2%)
13F Filers holding this stock: 189 61 (3.99%)
Aggregate 13F shares on 03/31/2020: 154.172 Million 83.941 Million
Aggregate 13F shares on 12/31/2019: 151.276 Million 78.287 Million
Percent change: 1.91% 7.22%
Funds creating new positions: 30 11
Funds Adding to an existing position: 72 27
Funds closing out their position: 47 23
Funds reducing their position: 62 22
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ALKS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALKS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

5.5 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

WYSENSKI NANCY

  • Director
0 2020-07-15 2

LANDINE MICHAEL J SVP, CORP DEV., ALKERMES, INC.

  • Officer
207,345 2020-07-14 10

DIXON WENDY L

  • Director
14,243 2020-06-30 1

COOKE SHANE

  • Director
94,320 2020-06-12 1

STEJBACH MARK

  • Director
8,131 2020-06-10 0

ROBINSON JAMES A. JR.

  • Director
23,453 2020-06-10 0

FRATES JAMES M

0 2020-06-09 5

HOPKINSON CRAIG C. EVP R&D, CHIEF MEDICAL OFFICER

  • Officer
14,833 2020-06-07 3

GAFFIN DAVID JOSEPH SVP, CLO, ALKERMES, INC.

  • Officer
60,934 2020-06-05 4

NICHOLS CHRISTIAN TODD SVP, CHIEF COMMERCIAL OFFICER

  • Officer
2,471 2020-06-05 2

POPS RICHARD F

  • Director
0 2020-05-29 13

BREYER ROBERT A

  • Director
0 2020-05-20 1

ANSTICE DAVID W

  • Director
0 2020-05-20 1

MITCHELL PAUL J

  • Director
0 2020-05-20 1

SNYDERMAN NANCY LYNN MD

  • Director
0 2020-05-20 1

GAYNOR RICHARD

  • Director
0 2020-05-20 4

WILSON FRANK ANDERS

  • Director
0 2020-05-20 3

BROWN IAIN MICHAEL SVP FINANCE & CAO, ALKS INC.

  • Officer
38,581 2020-05-13 4

HENWOOD GERALDINE PRESIDENT AND CEO

  • Officer
  • Director
291,194 2020-04-17 0

BLOOM FLOYD E

  • Director
0 2019-05-22 0

BIBERSTEIN KATHRYN L EVP/CAO/CCO/CRO ALKS INC;

  • Officer
182,073 2018-03-01 0

EHRICH ELLIOT EVP, R&D & CMO, ALKERMES, INC.

  • Officer
57,056 2017-05-28 0

PUGH GORDON G SVP, COO & CRO, ALKERMES, INC.

  • Officer
No longer subject to file 2016-12-31 0

PETERSON REBECCA SVP, CORPORATE COMMUNICATIONS

  • Officer
2,644 2015-10-05 0

BOTKIN JAMES L SVP, ALKERMES GAINESVILLE LLC

  • Officer
No longer subject to file 2013-12-31 0

SKALETSKY MARK B

  • Director
No longer subject to file 2013-11-13 0

ELAN CORP PLC

ELAN SCIENCE THREE LTD

  • 10% Owner
No longer subject to file 2012-03-13 0

RICH ALEXANDER

  • Director
0 2011-12-15 0

WALL MICHAEL A

  • Director
No longer subject to file 2011-09-16 0

BROECKER DAVID A PRESIDENT & CEO

  • Officer
106,616 2009-06-16 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

LANDINE MICHAEL J - Officer SVP, CORP DEV., ALKERMES, INC.

2020-07-14 M 5,523 $18.11 a 207,345 207,345.00 direct

LANDINE MICHAEL J - Officer SVP, CORP DEV., ALKERMES, INC.

2020-07-14 M 5,523 d 94,477 207,345.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments